Several mechanisms have been proposed whereby the increased risk among patients with T2D is associated with the metabolic disorders characteristic of this disease (e.g., hyperglycemia, insulin resistance, hyperinsulinemia or elevated levels of insulin-like growth factor 1—IGF-1) [58]. This evidence concerns the gene IGF1 and Insulin resistance.